Correlation of tumor relapse and elevated expression of survivin and vascular endothelial growth factor in superficial bladder transitional cell carcinoma

Genetics and Molecular Research

Volumn 12, Issue 2, 2013, Pages 1045-1053

  Sun, Y W ^a,b   Xuan, Q ^b   Shu, Q A ^b   Wu, S S ^b   Chen, H ^b   Xiao, J ^b   Xiang, P ^b   Zhu, Y P ^b   Wang, F L ^b   Zhao, S T ^a  

^a THE SECOND HOSPITAL OF SHANDONG UNIVERSITY   (China)

^b ANHUI PROVINCIAL HOSPITAL   (China)

Author keywords

Bladder cancer; Recurrence; Survivin; Vascular endothelial growth factor

Indexed keywords

BIOLOGICAL MARKER; SURVIVIN; VASCULOTROPIN;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER PROGNOSIS; CANCER RECURRENCE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PROTEIN EXPRESSION; RECURRENCE RISK; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TRANSITIONAL CELL CARCINOMA;

EID: 84876233932     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2013.April.2.21     Document Type: Article

References (25)

1. Athanassiadou P, Grapsa D, Athanassiades P, Gonidi M, et al. (2008). The prognostic significance of COX-2 and survivin expression in ovarian cancer. Pathol. Res. Pract. 204: 241-249.
2. Celen O, Kahraman I, Yildirim E and Berberoglu U (2004). Correlation of vascular endothelial growth factor (VEGF) and CEA with clinicopathological variables in colorectal cancer patients. Neoplasma 51: 293-299.
3. Deveraux QL and Reed JC (1999). IAP family proteins-suppressors of apoptosis. Genes Dev. 13: 239-252.
4. Fleshner NE, Herr HW, Stewart AK, Murphy GP, et al. (1996). The National Cancer Data Base report on bladder carcinoma. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 78: 1505-1513.
5. Grabowski P, Kuhnel T, Muhr-Wilkenshoff F, Heine B, et al. (2003). Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma. Br. J. Cancer 88: 115-119.
6. Ikeguchi M, Ueda T, Sakatani T, Hirooka Y, et al. (2002). Expression of survivin messenger RNA correlates with poor prognosis in patients with hepatocellular carcinoma. Diagn. Mol. Pathol. 11: 33-40.
7. Islam A, Kageyama H, Takada N, Kawamoto T, et al. (2000). High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 19: 617-623.
8. Jin Q, Hemminki K, Enquist K, Lenner P, et al. (2005). Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin. Cancer Res. 11: 3647-3653.
9. Kirkali Z, Chan T, Manoharan M, Algaba F, et al. (2005). Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 66: 4-34.
10. Koukourakis MI, Papazoglou D, Giatromanolaki A, Bougioukas G, et al. (2004). VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer 46: 293-298.
11. Monzo M, Rosell R, Felip E, Astudillo J, et al. (1999). A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J. Clin. Oncol. 17: 2100-2104.
12. Mori A, Wada H, Nishimura Y, Okamoto T, et al. (2002). Expression of the antiapoptosis gene survivin in human leukemia. Int. J. Hematol. 75: 161-165.
13. Plate KH, Breier G, Weich HA and Risau W (1992). Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359: 845-848.
14. Riedel F, Gotte K, Bergler W and Hormann K (2001). Inverse correlation of apoptotic and angiogenic markers in squamous cell carcinoma of the head and neck. Oncol. Rep. 8: 471-476.
15. Rohayem J, Diestelkoetter P, Weigle B, Oehmichen A, et al. (2000). Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients. Cancer Res. 60: 1815-1817.
16. Sato K, Sasaki R, Ogura Y, Shimoda N, et al. (1998). Expression of vascular endothelial growth factor gene and its receptor (flt-1) gene in urinary bladder cancer. Tohoku J. Exp. Med. 185: 173-184.
17. Schultz IJ, Kiemeney LA, Witjes JA, Schalken JA, et al. (2003). Survivin mRNA expression is elevated in malignant urothelial cell carcinomas and predicts time to recurrence. Anticancer Res. 23: 3327-3331.
18. Schultz IJ, Kiemeney LA, Karthaus HF, Witjes JA, et al. (2004). Survivin mRNA copy number in bladder washings predicts tumor recurrence in patients with superficial urothelial cell carcinomas. Clin. Chem. 50: 1425-1428.
19. Smith BD, Smith GL, Carter D, Sasaki CT, et al. (2000). Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma. J. Clin. Oncol. 18: 2046-2052.
20. Suzuki A, Ito T, Kawano H, Hayashida M, et al. (2000). Survivin initiates procaspase 3/p21 complex formation as a result of interaction with Cdk4 to resist Fas-mediated cell death. Oncogene 19: 1346-1353.
21. Swana HS, Grossman D, Anthony JN, Weiss RM, et al. (1999). Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N. Engl. J. Med. 341: 452-453.
22. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, et al. (2006). Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur. Urol. 49: 466-477.
23. Tran J, Rak J, Sheehan C, Saibil SD, et al. (1999). Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. Biochem. Biophys. Res. Commun. 264: 781-788.
24. Waters WB (1996). Invasive bladder cancer-where do we go from here? J. Urol. 155: 1910-1911.
25. Zhu H, Chen XP, Zhang WG, Luo SF, et al. (2005). Expression and significance of new inhibitor of apoptosis protein survivin in hepatocellular carcinoma. World J. Gastroenterol. 11: 3855-3859.